• Q/C Technologies posted a net loss of USD 1.24 million for the quarter ended March 31, 2026, widening from a net loss of USD 1.12 million a year earlier.
• Operating loss narrowed to USD 1.86 million from USD 2.47 million, as total operating expenses fell to USD 1.86 million from USD 2.47 million.
• General and administrative costs rose 26.72% to USD 1.07 million, while research and development spending dropped 66.97% to USD 510,534 on suspension of Phase 2b study of Isomyosamine.
• Other expense widened to USD 612,416 from USD 1.35 million of other income, driven by a USD 510,000 loss from changes in fair value of Series H derivative liabilities.
• Cash was USD 1.13 million, marketable securities were USD 11.85 million, while strategy remained centered on deploying LightSolver-licensed qc-LPU100 laser processing units for energy-efficient blockchain and cryptocurrency infrastructure.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Q/C Technologies Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-023751), on May 15, 2026, and is solely responsible for the information contained therein.